Core Viewpoint - Charoen Pokphand International (03839) experienced a decline of over 7%, currently trading at HKD 7.62 with a transaction volume of HKD 5.42 million [1] Financial Performance - For the nine months ending September 30, 2025, the company expects to report an unaudited consolidated profit attributable to shareholders of approximately USD 23.5 million, a significant increase from USD 4.3 million in the same period last year, representing a year-on-year growth of 447% [1] - The profit growth is primarily attributed to a substantial increase in revenue, reflecting the successful implementation of key strategies in developing major customer sales [1] Market Conditions - However, due to a slowdown in China's livestock industry, the demand for the company's veterinary pharmaceutical products is expected to decrease starting from the third quarter of 2025 [1] - The company anticipates that the unaudited quarterly profit attributable to shareholders for the three months ending September 30, 2025, will drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025 [1]

Core Viewpoint - Charoen Pokphand International (03839) experienced a decline of over 7%, currently trading at HKD 7.62, with a transaction volume of HKD 5.42 million [1] Financial Performance - For the nine months ending September 30, 2025, the company expects to report an unaudited net profit attributable to shareholders of approximately USD 23.5 million, a significant increase from USD 4.3 million in the same period last year, representing a year-on-year growth of 447% [1] - The profit growth is primarily attributed to a substantial increase in revenue, reflecting the successful implementation of key strategies in developing major customer sales [1] Market Conditions - The demand for the company's veterinary pharmaceutical products is expected to decrease due to a slowdown in China's livestock industry, starting from the third quarter of 2025 [1] - The company anticipates that its unaudited quarterly net profit attributable to shareholders for the three months ending September 30, 2025, will drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025 [1]

Group 1 - The company expects to achieve an unaudited consolidated profit attributable to shareholders of approximately $23.5 million for the nine months ending September 30, 2025, compared to $4.3 million for the same period ending September 30, 2024, indicating significant profit growth driven by a substantial increase in revenue [1] - The profit growth is attributed to the successful implementation of key strategies focused on developing large customer sales [1] - However, due to a slowdown in China's livestock industry, the demand for the company's animal health pharmaceutical products is expected to decrease starting from the third quarter of 2025 [1] Group 2 - The company anticipates that its unaudited quarterly profit attributable to shareholders for the three months ending September 30, 2025, will decline to approximately $6.5 million, down from $9.3 million for the three months ending June 30, 2025 [1]

Core Viewpoint - Charoen Pokphand Enterprises International (03839) expects to achieve an unaudited net profit attributable to shareholders of approximately $23.5 million for the nine months ending September 30, 2025, a significant increase compared to $4.3 million for the same period in 2024, driven by substantial revenue growth from successful implementation of key strategies targeting large clients [1] Financial Performance - The expected net profit for the nine months ending September 30, 2025, is approximately $23.5 million, up from $4.3 million for the nine months ending September 30, 2024 [1] - The anticipated unaudited quarterly net profit for the three months ending September 30, 2025, is expected to decrease to about $6.5 million, down from $9.3 million for the three months ending June 30, 2025 [1] Market Conditions - The growth in profit is primarily attributed to a significant increase in revenue, reflecting the successful implementation of strategies aimed at developing large client sales [1] - However, there is a noted decrease in demand for the company's veterinary pharmaceutical products due to a slowdown in China's livestock industry, which began to impact demand from the third quarter of 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 股東及潛在投資者在買賣本公司股份時務請審慎行事。 承董事會命 董事 李紹慶 香港，二零二五年十月二十一日 於本公告日期，董事會包括謝吉人先生（董事長及非執行董事）、李紹慶先生、李紹祝 先生、謝杰人先生、馬德壽先生（各人均為執行董事）、池添洋一先生（非執行董事）、 Surasak Rounroengrom 先生、鄭毓和先生、高明東先生及章曼琪女士（各人均為獨立非 執行董事）。 正大企業國際有限公司 （於百慕達註冊成立之成員有限責任公司） (股份代號：3839) 內幕消息 二零二五年九個月初步業績之預估盈利 本公告由正大企業國際有限公司（「本公司」連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09（2）條和證券及期貨條 例（香港法例第571章）第XIVA部項下的內幕消息條文 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 正大企業國際有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03839 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 787,389,223 | USD | | 0.1 | USD | | 78,738,922.3 | | 2 ...

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 (Incorporated in Bermuda with members' limited liability 於百慕達註冊成立之成員有限責任公司) (Stock Code 股份代號: 3839) 17 September 2025 The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.ctei.com.hk and on the HKEXnews website at www.hkexnews.hk. If you have requested to receive the Company's Corporate Communications (Note 1) in printed form, the Current Corporate Communication is enclosed. As a ...

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 (Incorporated in Bermuda with members' limited liability 於百慕達註冊成立之成員有限責任公司) (Stock Code 股份代號: 3839) 17 September 2025 Dear registered shareholder(s), Solicitation of electronic contact details To ensure timely receipt of the latest Corporate Communications and Actionable Corporate Communications(Note 2) , the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alte ...

CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 Incorporated in Bermuda with members' limited liability • Stock Code : 3839 於百慕達註冊成立之成員有限責任公 司 • 股份代 號：3839 INTERIM REPORT 2025 中期報告 Incorporated in Bermuda with members' limited liability • Stock Code : 3839 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正大企業國際有限公司 於百慕達註冊成立之成員有限責任公 司 • 股份代 號：3839 CHIA TAI ENTERPRISES INTERNATIONAL LIMITED 正 大 企 業 國 際 有 限 公 司 Contents 目 錄 INTERIM REPORT 2025 二零二五年中期報告 01 2 Management Discussion and Analysis 管理層討論及分析 6 Report ...

Core Viewpoint - Charoen Pokphand Enterprises International (03839) has seen a significant increase in stock price, rising over 570% year-to-date, with a current price of 10.02 HKD and a trading volume of 15.47 million HKD [1] Group 1: Strategic Partnership - On August 28, Muyuan Foods and Charoen Group signed a strategic cooperation agreement in Bangkok, Thailand, marking a collaboration between the world's first and third largest pig farming giants [1] - The partnership will focus on strategic planning, business integration, and global layout, promoting deep collaboration in areas such as feed, pig farming, slaughtering, food processing, talent, and capital [1] Group 2: Company Performance - Charoen Pokphand Enterprises International is a subsidiary of Charoen Group and is one of the world's leading producers of chlortetracycline [1] - According to Huaxin Securities, the global market for veterinary chlortetracycline is dominated by two companies, Jinhe Biology and Charoen Biology, which together account for over 90% of global production capacity, indicating a duopoly market structure [1] - The company's financial report shows a 768.36% year-on-year increase in net profit for the first half of the year, primarily driven by significant growth in the group's biochemical business, which focuses on animal health pharmaceutical products and chlortetracycline [1]